Journal article

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Douglas CA Taylor, Ankur Pandya, David Thompson, Paula Chu, Jennifer Graff, James Shepherd, Nanette Wenger, Heiner Greten, Rafael Carmena, Michael Drummond, Milton C Weinstein

The European Journal of Health Economics | SPRINGER | Published : 2009

DOI: 10.1007/s10198-008-0126-1

University of Melbourne Researchers

Citation metrics

22Web of Science
26Scopus

Keywords

Pravastatin
Social Sciences
Dose-Response Relationship, Drug
Markov Model
Scandinavian Simvastatin Survival
Health Care Sciences & Services
Humans
Coronary-Heart-Disease
Controlled-Trial
Decision Analysis
Statin Therapy
Cholesterol Lowering
Cost-Benefit Analysis
Follow-Up
Prognosis
Life Sciences & Biomedicine
Europe
Cardiovascular Disease
Secondary Prevention
Cholesterol Levels
Atorvastatin
Myocardial-Infarction
4s
Heptanoic Acids
Cardiovascular Diseases
Business & Economics
Pyrroles
Economics
Health Policy & Services
Anticholesteremic Agents
Science & Technology
Markov Chains
Cost-Effectiveness
Quality-Adjusted Life Years
Guidelines